These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9075499)

  • 21. Amphotericin B infused in 20% lipid emulsion.
    Ryan KA
    J Intraven Nurs; 1996; 19(3):123-5. PubMed ID: 8788829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute renal failure with amphotericin B in lipid emulsion.
    Gales MA; Gales BJ; Alford KM
    Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
    [No Abstract]   [Full Text] [Related]  

  • 23. Administration of amphotericin B in lipid emulsion.
    O'Neil MG; Lapointe M
    Crit Care Med; 1997 May; 25(5):892-3; author reply 893-4. PubMed ID: 9187614
    [No Abstract]   [Full Text] [Related]  

  • 24. Stability of amphotericin B and nystatin in antifungal mouthrinses containing sodium hydrogen carbonate.
    Groeschke J; Solassol I; Bressolle F; Pinguet F
    J Pharm Biomed Anal; 2006 Sep; 42(3):362-6. PubMed ID: 16740372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
    Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
    Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of amphotericin B in lipid emulsion.
    Devlin J; Bailey E; Zarowitz B
    Crit Care Med; 1997 May; 25(5):892; author reply 893-4. PubMed ID: 9187613
    [No Abstract]   [Full Text] [Related]  

  • 27. Enhanced stability and permeation potential of nanoemulsion containing sefsol-218 oil for topical delivery of amphotericin B.
    Hussain A; Samad A; Singh SK; Ahsan MN; Faruk A; Ahmed FJ
    Drug Dev Ind Pharm; 2015 May; 41(5):780-90. PubMed ID: 24654936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amphotericin B, its lipid formulations and conjugates with polymers.
    Kubicová L; Pravda M; Buchta V; Voprsalová M; Sedlák M
    Cent Eur J Public Health; 2004 Mar; 12 Suppl():S54-6. PubMed ID: 15141979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B.
    Hussain A; Singh VK; Singh OP; Shafaat K; Kumar S; Ahmad FJ
    Drug Deliv; 2016 Oct; 23(8):3101-3110. PubMed ID: 27854145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
    Azanza Perea JR; Barberán J
    Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simple Strategy for Taming Membrane-Disrupting Antibiotics.
    Yu Y; Sabulski MJ; Schell WA; Pires MM; Perfect JR; Regen SL
    Bioconjug Chem; 2016 Dec; 27(12):2850-2853. PubMed ID: 27801580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid complexes of amphotericin B: the competitive picture.
    Richardson MD
    J Med Microbiol; 1997 Mar; 46(3):185-7. PubMed ID: 9126817
    [No Abstract]   [Full Text] [Related]  

  • 34. Comment: expense of amphotericin B product.
    Andersen JM
    Ann Pharmacother; 1996 Nov; 30(11):1342. PubMed ID: 8913426
    [No Abstract]   [Full Text] [Related]  

  • 35. Amphotericin B toxicity reduced by administration in fat emulsion.
    Anderson RP; Clark DA
    Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability.
    Morand K; Bartoletti AC; Bochot A; Barratt G; Brandely ML; Chast F
    Int J Pharm; 2007 Nov; 344(1-2):150-3. PubMed ID: 17669608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Amphotericin B-intralipid 20% combination. In vivo evaluation of its tolerability].
    Débat Zoguéreh D; Poignard P; Sorriaux A; Brouqui P
    Ann Med Interne (Paris); 1997; 148(1):100-2. PubMed ID: 9137701
    [No Abstract]   [Full Text] [Related]  

  • 38. Visual compatibility of micafungin sodium and levofloxacin injections.
    Fleischbein E; Montgomery PA; Zhou CS
    Am J Health Syst Pharm; 2012 Dec; 69(24):2130. PubMed ID: 23230033
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of lipid emulsions for the i.v. administration of a new water soluble polyene antibiotic, SPK-843.
    Mozzi G; Benelli P; Bruzzese T; Galmozzi MR; Bonabello A
    J Antimicrob Chemother; 2002 Feb; 49(2):321-5. PubMed ID: 11815574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Collaborative study for the establishment of the second international standard for amphotericin B.
    Rautmann G; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):1-13. PubMed ID: 20223186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.